Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...

In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

Association driven by fewer major amputations ...

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and ...

By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Fewer adolescents in the GLP-1 receptor agonist group vs ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

The researchers found that patients taking GLP-1 RAs had a significantly reduced incidence of revision FESS versus the non-GLP-1 RA group at one-year (risk ratio [RR], 0.64) and five-year follow-up ...

These findings are particularly relevant given the growing number of patients admitted to the ICU who are receiving GLP-1 ...